anti-Nipah_003
| anti-Nipah_ID | anti-Nipah_003 |
| anti-Nipah Drug | Ac-VALDPI DISIVLN Kl KSDLEESKEWIRRSNKILDSI-GSGSGdPEG4-C-TOCO-NH2 |
| Nipah virus strain | NiV (UMMC1 ) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | in-vitro |
| Models used to test anti-Nipah activity | 293T |
| Mode of infection to test anti-Nipah activity | NA |
| Viral titer to test anti-Nipah activity | NA NA |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | NA |
| Duration of Drug delivery for anti-Nipah activity | NA |
| Drug concentration used to test anti-Nipah activity | 8 nM |
| Assays used to test anti-Nipah activity | beta-galactosidase complementation assay |
| anti-Nipah activity | Decrease [Inhibitory concentration (50 %)] |
| References | Mathieu C, Porotto M, Figueira TN, Horvat B, Moscona A Fusion Inhibitory Lipopeptides Engineered for Prophylaxis of Nipah Virus in Primates. J Infect Dis. 2018 Jun 20;218(2):218-227. doi: 10.1093/infdis/jiy152. |
| Comments | The experiments provide a proof of concept for the use of antifusion lipopeptides for prophylaxis of lethal NiV |